BioMarin Pharmaceutical Inc.
105 Digital Drive
Novato
California
94949
United States
Tel: 415-506-6700
Fax: 415-382-7427
Website: http://www.bmrn.com/
Email: ir@bmrn.com
About BioMarin Pharmaceutical Inc.
At BioMarin, we focus on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored.
BioMarin offers a friendly, fast-paced, collegial environment where success is measured by both the individual and collective efforts of hundreds of talented scientists, business professionals, technical specialists and experts in a variety of fields from sales and marketing, to finance, to manufacturing, to clinical and regulatory operations.
BioMarin is growing rapidly to support the development and global commercialization of breakthrough drugs to treat rare genetic diseases. The company’s product portfolio comprises seven approved products and multiple clinical and pre-clinical product candidates.
You can make it happen at BioMarin, where the unique combination of big-company success in a small-company environment provides unparalleled opportunity for individual contributions and growth.
What makes working here unique? At BioMarin, we feel the intense tie between the work we do and the life-changing results it delivers. Our focus on rare disease gives us the rare opportunity to truly impact lives.
586 articles with BioMarin Pharmaceutical Inc.
-
5 Biotechs Drawing Buyout Buzz in 2018
1/24/2018
Here are five possible acquisition targets to keep an eye on. -
BioMarin Receives Anticipated Notification of PDUFA Extension for Pegvaliase BLA to May 28, 2018
12/22/2017
In a notice received from the FDA, the PDUFA Goal Date for pegvaliase has been extended by three months to May 28, 2018.
-
BioMarin Doses First Patient in Global GENEr8-1 Phase III Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
12/19/2017
BioMarin announced today that it has dosed the first patient in the global GENEr8-1 Phase 3 study with the 6e13 vg/kg dose for valoctocogene roxaparvovec.
-
4 Possible Biotech Takeover Targets for 2018
12/12/2017
This year wasn't big for mergers and acquisitions in biopharma, particularly compared to 2015 and 2016. -
BioMarin Provides 1.5 Years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at 59th ASH Annual Meeting Concurrent With NEJM Publication
12/11/2017
BioMarin announced today an update to its previously reported results of an open-label Phase I/II study of valoctocogene roxaparvovec.
-
BioMarin Highlights New Results for Gene Therapy Valoctocogene Roxaparvovec at the 2017 ASH Meeting
12/11/2017
With the 4e13 vg/kg dose, the three patients with the longest follow-up have Factor VIII activity levels that are in or near to the normal range with both median and mean values of 49%.
-
Stem Cells Ready for Prime Time?
11/27/2017
A look at the FDA's long-awaited guidelines on how it will regulate regenerative medicine products, including stem cells. -
BioMarin was awarded the voucher when it received approval of Brineura.
-
BioMarin Announces Third Quarter 2017 Financial Results
10/27/2017
BioMarin today announced financial results for the third quarter ended September 30, 2017.
-
BioMarin announced that the FDA granted its valoctocogene roxaparvovec for Hemophilia A Breakthrough Therapy Designation.
-
BioMarin updated the investment community on the Company's development portfolio at R&D Day in New York.
-
BioMarin To Host Third Quarter 2017 Financial Results Conference Call And Webcast On Thursday, October 26 At 4:30 P.M. ET
10/10/2017
-
BioMarin Appoints Robert J. Hombach, Former Baxalta CFO And COO, To Board Of Directors
10/3/2017
-
FDA Not Currently Planning To Hold Advisory Committee Meeting For BioMarin's Pegvaliase Biologics License Application (BLA)
9/15/2017
-
BioMarin Presents Interim Data Of Phase I/II Study Of BMN 250 For Treatment Of Sanfilippo B Syndrome (MPS IIIB) At 13th International Congress Of Inborn Errors Of Metabolism (ICIEM) 2017
9/6/2017
-
FDA Accepts BioMarin's Pegvaliase Biologics License Application (BLA) And Grants Priority Review Designation
8/30/2017
-
BioMarin Announces Exercise In Full Of Underwriters' Option To Purchase Additional 0.599% Senior Subordinated Convertible Notes Due 2024
8/24/2017
-
Bay Area’s BioMarin Expands With The World's “First and Largest” Gene Therapy Manufacturing Plant
8/9/2017
-
BioMarin Announces Offering Of $450 Million Of Senior Subordinated Convertible Notes Due 2024
8/8/2017
-
BioMarin Announces Second Quarter 2017 Financial Results
8/3/2017